What is the LSX Congress USA?

LSX World Congress USA will replicate the unique dynamics and high-quality senior audience that has become the hallmark of LSX events around the world. In September 2023, we’ll be gathering North America’s leading Biotech, Medtech and Healthtech CEOs for a 2-day executive conference, in-person 1-2-1 partnering and company showcasing opportunities.

The CEOs from our network will be joined by the sectors most active investors, big pharma and commercial leaders as well as a selection of the highest-quality, trusted advisors. So, pack your bags, get out from behind your desks and join us in glorious Boston for some inspiring content, quality peer-to-peer discussion and high-level networking!

5 reasons to choose LSX USA

 

LSX USA focuses almost exclusively on 3 main profiles – executives of life science and healthcare innovators (Biotech, Medtech and Healthtech), investors an large pharma/medtech. That means our delegation is extremely focussed, extremely relevant and perfectly matched for partnering and investment.


LSX USA occupies that sweet spot between smaller-scale conferences and large-scale exhibitions/trade shows. The event is intimate enough to provide quality attendees in an accessible way (800+ attendees in 2023) but also has enough critical mass to cover a wide range of companies at all stages of development.


LSX USA will be bringing over 200 of the world’s most active investors to Boston. Fundraising? There’s no better place to be.


LSX USA has a highly sophisticated, easy to use and widely adopted 1-2-1 partnering platform. All our attendees are highly qualified and available to contact via a huge range of search criteria. Other events say they do ‘partnering’. We’re the experts at it.


Healthcare is converging! As the lines between biopharma, healthtech/digital health and traditional medtech are blurring, LSX USA is the only event in the world dedicated to covering all 3 areas and encouraging learning, partnering and networking across the whole healthcare ecosystem.